Last reviewed · How we verify
Patent cliff explained
What creates the cliff
Pharmaceutical patents have 20-year terms from filing, but the meaningful protection is usually much shorter — typically 10-14 years of marketed exclusivity once you factor in development time + secondary protections. When the composition-of-matter patent expires + exclusivity periods lapse + generic manufacturers complete their bioequivalence (or biosimilarity) work, multiple competitors can enter the market simultaneously.
Erosion dynamics: small molecule vs biologic
Small-molecule generics: typical erosion of 30-60% in year 1, dropping to 80-95% revenue loss by year 2-3 as multiple manufacturers compete. Pricing falls 60-90%+ vs the originator. Biosimilars: slower erosion (10-25% year 1, 40-60% by year 3) because manufacturing complexity is real and switching friction matters. Pricing falls 15-35% only.
Defensive strategies
Originators defend with: (1) formulation patents — protect dose form, delivery, drug-device combinations (often extend 2-5 years); (2) Authorized Generics — license a generic version pre-cliff to capture market share before "true" generics arrive; (3) Pay-for-delay — settlements with generic challengers to delay entry (now substantially restricted by FTC + DOJ); (4) Next-gen molecules — develop improved versions before the cliff (rivaroxaban → factor XI inhibitors); (5) Indication expansion — broaden the brand into new patient populations.
How to forecast a cliff
Composition-of-matter patent expiry is the headline date but isn't always the operative cliff. Look at: (a) listed Orange Book patents (small molecule) or Purple Book (biologic); (b) any patent-term-extensions granted; (c) data + market exclusivity periods (5 years NCE / 12 years biologic / 7 years orphan); (d) any settlements or litigation outcomes that delay entry; (e) generic / biosimilar sponsor filings already in progress.
Historical examples
Lipitor (atorvastatin, 2011): peak $13B revenue → <$2B within 3 years. Plavix (clopidogrel, 2012): peak $9B → <$1B within 18 months. Humira (adalimumab, 2023): peak $21B → projected $5-10B by 2027 as biosimilars accumulate. Each cliff is a major event in the originator's P&L.
FAQ
When does Humira go fully generic?
Humira biosimilars launched in the US in 2023 after EU launches in 2018. Revenue is projected to drop from $21B (2022 peak) to $5-10B by 2027. Still a major drug — but biosimilars are accumulating slower than small-molecule generics would.
What's the biggest upcoming patent cliff?
See our /patents tracker. Major upcoming: Ustekinumab (Stelara, immunology), Aflibercept (Eylea, ophthalmology), Denosumab (Prolia/Xgeva, bone). Combined ~$30B+ revenue at stake.
Can the FDA delay a patent cliff?
No — FDA doesn't set patent terms. But the FDA does grant 5-year (NCE) or 12-year (biologic) data exclusivity periods that prevent ANDAs/biosimilar applications from being approved early, even if the patent has expired.
Why are biosimilar discounts smaller than generic discounts?
Biosimilars cost $100-300M to develop vs $1-5M for small-molecule generics. Manufacturing is harder. Switching friction is real (prescribers + patients are cautious). And fewer biosimilar entrants → less competition.